Navigating the ADHD Medication Shortage in 2024: Understanding Challenges and Exploring Solution

In 2024, individuals and families affected by ADHD are grappling with a significant medication shortage. This shortage, impacting popular medications like Adderall and its generic equivalents, has left many in a state of uncertainty and difficulty. We hope this article sheds light on explaining the ADHD medication shortage and its impacts to patients in families.

The Situation in 2022-2023

Initially, the FDA reported a shortage of immediate-release Adderall due to manufacturing delays at Teva Pharmaceuticals, one of the major distributors in the U.S.

This shortage has expanded to include various generic equivalents and other stimulant ADHD medications such as Ritalin, Concerta, and now generic Vyvanse.

The shortage, as highlighted by the FDA, is partly due to labor shortages at key manufacturers like Teva Pharmaceuticals. Additionally, there’s been an increased demand in the U.S. market, partly due to relaxed prescribing rules during the pandemic.

How ADHD Medications Work

ADHD medications, including Adderall, Vyvanse, Concerta and Ritlain, are primarily stimulants that increase neurotransmitters like dopamine and norepinephrine in the brain, aiding in focus and reducing symptoms like impulsivity and hyperactivity. These medications can be extremely helpful for patients with ADHD where patients typically struggle with executive functioning in both the school and work environments as well as with interpersonal relationships.

You may also read our article about ADHD treatment options What Does ADHD Look Like in Adults? The Main Signs and Symptoms.

The Broader Impact

The shortage has forced many to switch medications or go off medication entirely, impacting daily functioning and long-term outcomes, especially in education and work settings. Many patients have had difficulty finding their maintenance medication at the local pharmacy. This has caused patients to be without their medication or needing to ask their prescriber for alternative treatment in between appointments. This can cause frustration for patients and family members as switching medications may not be cost effective or alternative medications may not work as well for executive dysfunction. Patients and parents may have to drive long distances, sometimes 2 to 3 hours, just to find their medication at a pharmacy, causing missed work and/or school.

Exploring the Causes

Demand has dramatically outpaced supply. While other manufacturers produce amphetamine mixed salts, their output hasn’t met the growing market demand.

From 2012 to 2021, there was almost a 50% increase in the dispensing of stimulants, driven by factors like reduced stigma and increased ADHD awareness. Regulatory constraints also play a role. Stimulants are controlled substances, and the DEA sets production limits, which has contributed to the shortage.

The Current Scenario

As of late 2023, the FDA lists 40 different formulations and dosages of Adderall and its generics in shortage. Some manufacturers predict increased supply availability between October 2023 and February 2024. The FDA and DEA have urged manufacturers with unused production quotas to relinquish them so others can increase production.

Navigating the Shortage

Explore alternatives with your healthcare provider, considering other stimulants or non-stimulant options.
If your medication is delayed or on backorder, ask your provider for a 7-day supply of an alternative medication until your original prescription is back in stock.
Take “drug holidays” where you do not take the full dose of your medication on weekends or days where work is not as demanding if your medication is on backorder with the pharmacy.
Ask your provider for a paper Rx that you can pick up from their office in the event that the pharmacies will not tell you about their inventory over the phone.
Utilize resources like FDA and ASHP websites for current information on drug availability. You may visit the link here ASHP.
Consider integrating behavioral modifications and therapies, especially if medication adjustments are required. You may read more on Tips on How to Focus with ADHD.

Looking Ahead

The shortage is expected to ease as supply aligns with demand, but there’s no definitive timeline for resolution. The FDA and DEA are working to address the shortage, with potential quota adjustments and collaborations with pharmaceutical companies. See the letter to the joint commission here Joint DEA FDA Letter.

Conclusion

The ADHD medication shortage in 2024 is a complex issue influenced by factors like manufacturing delays, regulatory constraints, and a significant increase in demand. By staying informed and working closely with healthcare providers, patients and families can navigate these challenging times and explore viable alternatives for effective ADHD management.

Sources and Additional Resources